Intracellular metabolic signaling pathways

Intracellular metabolic signaling pathways represent the integrated networks of molecular interactions that govern how cells sense and respond to nutrient availability and energy demands (StatPearls: Metabolic Signaling). These pathways, including the insulin signaling pathway, the adenosine monophosphate-activated protein kinase (AMPK) pathway, and the mechanistic target of rapamycin (mTOR) pathway, are critical for maintaining cellular and systemic homeostasis (NCBI: PMC4045293). Dysregulation of these signaling networks is central to the pathogenesis of metabolic disorders like type 2 diabetes and obesity, as well as the metabolic reprogramming observed in cancer cells to support uncontrolled proliferation (PubMed: 27633323). Because this term encompasses a vast array of distinct proteins and biochemical reactions, it is classified as a broad biological process rather than a single discrete therapeutic target. Pharmacological intervention typically focuses on specific enzymes or receptors within these pathways, such as the activation of AMPK by metformin or the inhibition of mTOR by rapalogs, to achieve therapeutic effects (PubChem: Metformin, Sirolimus). The inherent complexity and extensive crosstalk between these pathways present significant challenges for drug development, particularly regarding the risk of systemic toxicity and the emergence of compensatory resistance mechanisms.

Other names

Metabolic signaling cascadesNutrient sensing pathwaysIntracellular metabolic networksCellular metabolic signaling

Therapeutic agents modulate specific nodes within these pathways, such as activating adenosine monophosphate-activated protein kinase (AMPK) or inhibiting the mechanistic target of rapamycin (mTOR), to restore metabolic homeostasis or suppress pathological cell proliferation.